In this question-and-answer discussion of "generic" biologics, the authors contend small changes in manufacturing of biologics dramatically affect the safety and efficacy of the therapeutic molecule.
Gillian R. Woollett
Advertisement
Articles by Gillian R. Woollett
Advertisement
Latest Updated Articles
Biologics: Can There Be Abbreviated Applications, Generics, or Follow-On Products?Published: July 1st 2003 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
